ARCHIVES

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

This article is from The Cancer Letter archive.

Vol. 30 No. 46 | December 10, 2004

Download PDF Visit The Full Archive

Related Articles

Group Chairmen Reject DCT’s Agenda For Clinical Trials Review, demand Right To Select Speakers

June 30, 1978

NCI Opens Negotiations With Litton-Bionetics For Renewal of $10 Million Frederick Contract

March 1, 1974

AACR President Kripke Calls For Dedicated Translational Research

March 11, 1994

Hopkins Challenges Litton For Research Contract At FCRF

April 16, 1982

Central Line Safety Intervention Lowers Patient Infection Rate

October 25, 2013

UNM Cancer Center Appoints Four Leaders

May 24, 2013